Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PCVX – Vaxcyte, Inc.

Vaxcyte, Inc.
PCVX
$46.14
Name : Vaxcyte, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $6,040,014,848.00
EPSttm : -4.85
finviz dynamic chart for PCVX
Vaxcyte, Inc.
$46.14
1.61%
$0.73

Float Short %

8.53

Margin Of Safety %

Put/Call OI Ratio

1.52

EPS Next Q Diff

0.03

EPS Last/This Y

-1.51

EPS This/Next Y

-0.91

Price

46.13

Target Price

99.89

Analyst Recom

1.2

Performance Q

21.33

Relative Volume

0.6

Beta

1.34

Ticker: PCVX




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-02PCVX44.690.570.388860
2025-12-03PCVX47.670.570.308865
2025-12-04PCVX46.070.570.038892
2025-12-05PCVX46.490.570.008903
2025-12-08PCVX46.190.570.058912
2025-12-09PCVX44.710.570.258934
2025-12-10PCVX43.480.570.508937
2025-12-11PCVX44.590.570.298935
2025-12-12PCVX44.490.571.008938
2025-12-15PCVX44.370.570.508935
2025-12-16PCVX43.630.579.008937
2025-12-17PCVX43.030.570.078955
2025-12-18PCVX43.730.560.338950
2025-12-19PCVX46.430.560.018968
2025-12-22PCVX48.071.770.084138
2025-12-23PCVX47.841.700.114210
2025-12-26PCVX46.991.375.784614
2025-12-29PCVX46.561.3913.944669
2025-12-30PCVX45.41.520.804920
2025-12-31PCVX46.131.520.014923
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-02PCVX44.70-42.3- -5.31
2025-12-03PCVX47.70-42.3- -5.31
2025-12-04PCVX46.06-42.3- -5.31
2025-12-05PCVX46.48-42.3- -5.31
2025-12-08PCVX46.18-42.3- -5.31
2025-12-09PCVX44.74-42.3- -5.31
2025-12-10PCVX43.43-42.3- -5.31
2025-12-11PCVX44.56-42.3- -5.31
2025-12-12PCVX44.50-42.3- -5.31
2025-12-15PCVX44.34-42.3- -5.31
2025-12-16PCVX44.34-42.3- -5.31
2025-12-17PCVX43.04-42.3- -5.31
2025-12-18PCVX43.72-42.3- -5.31
2025-12-19PCVX46.36-42.3- -5.31
2025-12-22PCVX48.11-42.3- -5.31
2025-12-23PCVX47.92-42.3- -5.31
2025-12-26PCVX47.00-42.3- -5.31
2025-12-29PCVX46.57-42.3- -5.31
2025-12-30PCVX45.38-42.3- -5.31
2025-12-31PCVX46.13-42.3- -5.31
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-02PCVX0.00-3.897.36
2025-12-03PCVX0.00-3.897.36
2025-12-04PCVX0.00-3.897.36
2025-12-05PCVX0.00-3.897.36
2025-12-08PCVX0.00-3.917.36
2025-12-09PCVX0.00-3.917.36
2025-12-10PCVX0.00-3.918.12
2025-12-11PCVX0.00-3.918.12
2025-12-12PCVX0.00-3.918.12
2025-12-15PCVX0.00-3.918.11
2025-12-16PCVX0.00-3.918.11
2025-12-17PCVX0.00-3.918.11
2025-12-18PCVX0.00-3.918.11
2025-12-19PCVX0.00-3.918.11
2025-12-22PCVX0.00-3.908.11
2025-12-23PCVX0.00-3.908.11
2025-12-26PCVX0.00-3.908.53
2025-12-29PCVX0.00-3.908.53
2025-12-30PCVX-0.29-3.908.53
2025-12-31PCVX-0.29-3.908.53
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-1.56

Avg. EPS Est. Current Quarter

-1.45

Avg. EPS Est. Next Quarter

-1.53

Insider Transactions

-0.29

Institutional Transactions

-3.9

Beta

1.34

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

12

Fair Value

Quality Score

9

Growth Score

18

Sentiment Score

17

Actual DrawDown %

61.9

Max Drawdown 5-Year %

-76.2

Target Price

99.89

P/E

Forward P/E

PEG

P/S

P/B

2.07

P/Free Cash Flow

EPS

-4.92

Average EPS Est. Cur. Y​

-5.31

EPS Next Y. (Est.)

-6.22

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.6

Return on Equity vs Sector %

-50

Return on Equity vs Industry %

-34.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

Vaxcyte, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 414
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
stock quote shares PCVX – Vaxcyte, Inc. Stock Price stock today
news today PCVX – Vaxcyte, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PCVX – Vaxcyte, Inc. yahoo finance google finance
stock history PCVX – Vaxcyte, Inc. invest stock market
stock prices PCVX premarket after hours
ticker PCVX fair value insiders trading